COVID-19 trials registries data warehouse

http://ensaiosclinicos.gov.br/rg/RBR-399t4g5

Fernanda Corrêa

fecorrea@uninove.br

2021-06-07

Not recruiting

RCT

Randomized

Factorial

Blind label

single-center

Treatment

Patients over 18 years of age, confirmed diagnosis of COVID-19 from moderate to severe, be able to understand the stimulation treatment that will be performed, receiving supplemental oxygen, non-invasive ventilation, but without being intubated

cochlear implant, have uncontrolled diabetes and hypertension.

2

Universidade Nove de Julho

18

100

Brazil

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

0

Inflammatory panelTo analyze the inflammatory panel; interleukin 6 (IL-6); interleukin-10; cortisol and C-reactive protein (CRP) will be analyzed. Blood samples will be collected by venipuncture. The blood (15 ml) will be collected in a tube containing protease inhibitor and EDTA and will be immediately centrifuged (3000 rpm; 15 min; 4 ° C). The plasma will be transferred to microcentrifuge tubes (1.5 ml) and stored at -80 ° C until analysis.The concentrations of IL-6; IL-10 and cortisol will be measured in plasma by the ELISA method (Enzyme-Linked Immuno-Sobent Assay) and competitive chemiluminescent immunoassay following the manufacturer's recommendations. The ELISA plates will be sensitized with 100 g / ml of the capture antibody to IL-6; IL-10 and cortisol (Human Quantikine ELISA Kit D6050; Human Quantikine ELISA Kit D100B and cortisol parameter KGE008B) and incubated overnight at 4 ° C. The plates will be washed the next day using a washing solution (PBS 0.05% Tween 20). IL-6 plates will be blocked and incubated for two hours at room temperature. After incubation; the plates will be washed again and the standard curves will be added. The curves will start at 8;000 pg / ml. The plates will be incubated for two hours at room temperature and; at the end; they will be washed. Detection antibodies to IL-6 will be added; and the plates will be incubated again at room temperature for two hours; and washed after that time. Then; streptavidin-HRP will be added at a dilution of 1/200; and the plates will be incubated for 20 minutes at room temperature; being washed after finishing. Substrate (urea peroxide and TMB; 1/1 proportion) will be added; which will develop a color proportional to the antigen present in the sample. This reaction will be blocked by the addition of stop solution (H2SO4 2M); and the intensity of that color will be measured immediately in the ELISA reader; using a wavelength of 450nm.Quantitative determination of CRP will be performed by nephelometry (Dade-Behring N High Sensitivity CRP). Polystyrene particles coated with a monoclonal anti-PCR antibody will agglutinate when mixed with patients containing PCR. The light intensity is directly proportional to the PCR concentration of the sample. The concentration of the PCR (in mg / l of serum) tested in the different dilutions will be known through calculations obtained from a curve prepared with the standard serum.

Not reported

[{"arm_notes": "", "treatment_id": 903, "treatment_name": "Non-invasive vagus nerve stimulator", "treatment_type": "Medical device", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]